Form 4: Vincerx Pharma Director Laura I. Bushnell Acquires Stock Options
SEC Form 4 Filing
Director Laura I. Bushnell acquired 15,000 stock options in Vincerx Pharma, Inc. on May 23, 2024.
Summary
- On May 23, 2024, Laura I. Bushnell, a director of Vincerx Pharma, Inc., acquired 15,000 stock options.
- The options have an exercise price of $0.7036.
- The options vest fully on the earlier of May 23, 2025, the next annual meeting of stockholders, or a change of control, contingent on continued service.
- The options expire on May 22, 2034.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align management's interests with those of the shareholders.
Stakeholder Impact
- The granting of stock options to a director can align their interests with those of shareholders, potentially incentivizing them to increase company value.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of transaction: Laura I. Bushnell acquired 15,000 stock options. |
| 05/23/2025 | Earliest vesting date for the stock options, contingent on continued service. |
| 05/22/2034 | Expiration date of the stock options. |
| 05/28/2024 | Date of signature for the Form 4 filing. |
Keywords
Vincerx Pharma, Stock Options, Director, Laura I. Bushnell, Beneficial Ownership, Form 4, VINC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.